{{Rsnum
|rsid=1542178
|Gene=NPAS2
|Chromosome=2
|position=100979013
|Orientation=minus
|GMAF=0.2355
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=AC016738.3,NPAS2
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 52.2 | 37.2 | 10.6
| HCB | 59.1 | 33.6 | 7.3
| JPT | 62.8 | 35.4 | 1.8
| YRI | 95.2 | 4.8 | 0.0
| ASW | 82.1 | 17.9 | 0.0
| CHB | 59.1 | 33.6 | 7.3
| CHD | 65.1 | 31.2 | 3.7
| GIH | 56.4 | 39.6 | 4.0
| LWK | 93.6 | 6.4 | 0.0
| MEX | 43.1 | 46.6 | 10.3
| MKK | 89.0 | 11.0 | 0.0
| TSI | 43.1 | 49.0 | 7.8
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs1542178
|Name_s=
|Gene_s=NPAS2
|Feature=
|Evidence=PubMed ID:19176441
|Annotation=This variant is associated with end-of-induction minimal risidual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) from 2 independent cohorts (GWAS result). Risk Allele: G, MAF= 0.28, combined P value= 9.50E-05.
|Drugs=
|Drug Classes=
|Diseases=Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma
|Curation Level=Curated
|PharmGKB Accession ID=PA162470184
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs1542178
|overall_frequency_n=100
|overall_frequency_d=122
|overall_frequency=0.819672
|n_genomes=50
|n_genomes_annotated=0
|n_haplomes=82
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}